**Background of SARS-CoV-2 N Antibody**
The SARS-CoV-2 nucleocapsid (N) protein is a structural protein critical for viral RNA packaging and replication. During infection, the N protein is highly expressed, making it a primary target for the host immune response. Antibodies against the N protein (anti-N antibodies) emerge as part of the adaptive immune response, typically detectable 1–3 weeks post-infection. Unlike antibodies targeting the spike (S) protein, anti-N antibodies are not neutralizing but serve as key markers for diagnosing prior SARS-CoV-2 exposure, especially in serology assays.
N antibody detection is widely used in seroprevalence studies to estimate past infections, complementing molecular tests (e.g., PCR). IgG anti-N antibodies often persist for months, though their longevity varies among individuals. Notably, most COVID-19 vaccines (e.g., mRNA vaccines) induce antibodies against the S protein but not the N protein, allowing differentiation between vaccine-induced and infection-induced immunity. However, this distinction has blurred with the emergence of hybrid immunity (vaccination plus infection) and updated vaccines incorporating N protein targets in some cases.
Studies suggest N protein mutations are less frequent compared to the S protein, making N-based assays relatively stable across variants. Nevertheless, certain variants (e.g., Omicron sublineages) harbor N protein mutations that may affect antibody binding, underscoring the need for ongoing surveillance. Beyond diagnostics, research explores N antibodies' role in disease progression, immune modulation, and potential therapeutic applications, though their clinical utility remains secondary to neutralizing S antibodies.
Overall, N antibodies remain vital tools for understanding infection dynamics, immunity breadth, and viral evolution.